Immutep’s Eftilagimod Alfa Data on Soft Tissue Sarcoma Set for ESMO 2026
Event summary
- Immutep’s abstract on EFTISARC-NEO Phase II trial accepted for ESMO Congress 2026.
- Study evaluates eftilagimod alfa in combination with pembrolizumab and radiotherapy for soft tissue sarcoma (STS).
- Presentation scheduled as an ePoster (#3788eP) during the October 23–27 event in Madrid.
- First author is Pawel Teterycz, M.D., from MSCNRIO in Warsaw, Poland.
The big picture
Immutep’s ESMO presentation comes as late-stage immunotherapy developers race to demonstrate differentiated efficacy. The focus on HRQoL metrics underscores a shift toward patient-centric endpoints, particularly in rare cancers like STS where treatment options remain limited. Success here could bolster efti’s standing alongside PD-1 inhibitors like pembrolizumab.
What we're watching
- Clinical Validation
- Whether EFTISARC-NEO data strengthens efti’s profile as a neoadjuvant therapy for STS.
- Regulatory Pathway
- How ESMO 2026 feedback may influence future trial designs or approval strategies.
- Competitive Positioning
- The pace at which Immutep can differentiate efti in the crowded immuno-oncology space.
Related topics